Develops a pipeline of injectable and oral therapies, including GLP-1/GIP receptor dual agonists and oral small molecule GLP-1 agonists, for chronic weight management and type 2 diabetes. These therapies aim to provide differentiated treatment options backed by clinical evidence from multiple trials, addressing the growing prevalence of obesity and its related metabolic conditions.
Funding
$400M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCRIFounders
Product
Problem
Obesity and type 2 diabetes are increasingly prevalent and require more effective therapeutic interventions. Current treatments may not provide sufficient weight management or glycemic control for all patients, highlighting the need for differentiated pharmacological options.
Solution
Kailera Therapeutics is developing a pipeline of injectable and oral therapies targeting chronic weight management and type 2 diabetes. Their portfolio includes GLP-1/GIP receptor dual agonists, oral small molecule GLP-1 agonists, and GLP-1/GIP/glucagon receptor tri-agonists. These therapies are designed to offer differentiated treatment options, supported by clinical evidence, to address the unmet needs in managing obesity and related metabolic conditions. The company's lead program, KAI-9531, an injectable GLP-1/GIP receptor dual agonist, has demonstrated compelling Phase 2 results in obesity and diabetes.
Target Audience
The primary target audience includes individuals with obesity and type 2 diabetes, as well as healthcare providers specializing in endocrinology and metabolic disorders.
Features
- KAI-9531: Injectable GLP-1/GIP receptor dual agonist in Phase 2 clinical development for obesity and type 2 diabetes.
- KAI-7535: Oral small molecule GLP-1 receptor agonist in clinical development for obesity and type 2 diabetes.
- KAI-9531 Oral: Oral tablet formulation of the GLP-1/GIP receptor dual agonist in preclinical development.
- KAI-4729: Injectable GLP-1/GIP/glucagon receptor tri-agonist in preclinical development.
- Programs licensed from Jiangsu Hengrui Pharmaceuticals, with existing clinical data from multiple trials.